Immunotherapy of Prostate Cancer With Genetically Enhanced Tumor-Specific T-Cell Precursors
Abstract
Precursor (Pre) T cells, when adoptively transferred further develop in the thymus into mature T cells, that is capable of lysing tumors. The overall objective of this project is to develop an effective off the shelf adoptive cell therapy with PreT cells targeting prostate cancer. To enhance the anti-tumor activity of PreT cells we transduced these cells with a chimeric antigen receptor (CAR)-Pz1 targeting the prostate cancer associated antigen - prostate specific membrane antigen (PSMA). Here we show that prostate cancer specific PreT cells can be generated by expressing CARs targeting human PSMA. T cells derived from the adoptively transferred PreT cells develop in thymic and extrathymic sites and prolong survival of prostate cancer bearing recipients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2011
- Accession Number
- ADA549122
Entities
People
- Marcel Van Den Brink
Organizations
- Memorial Sloan Kettering Cancer Center